Search Results
Your search for ,HIS matches 4456 pages
Showing 601 - 650Steven A. Rosenberg, MD, PhD, Recognized With 2022 Pezcoller Foundation–AACR International Award
The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research was presented to Steven A. Rosenberg, MD, PhD, at the Association’s 2022 Annual Meeting, held in New Orleans. Dr. Rosenberg was honored for his discovery and ...
Researchers Develop and Monitor Approaches to Fix Blood Vessel Abnormalities That Make Tumors Difficult to Treat
Tumors send out signals that impair normal blood flow, which makes them hard to treat with multiple therapies, including radiation, chemotherapy, targeted therapies, and immunotherapy. Impaired blood supply creates an environment low in oxygen levels, which causes the tumors to take on aggressive...
Study Points to Expanded Genomic Testing to Benefit Children and Young Adults With Cancer
New findings from researchers at Memorial Sloan Kettering Cancer Center published by Shukla et al in Nature Communications reported the results of using a comprehensive sequencing approach on 114 pediatric, adolescent, and young adult patients with solid tumors. The researchers found that their...
Colonoscopy After Positive FIT Test May Reduce Risk of Death From Colorectal Cancer
Recent research underlines the importance of following up with a colonoscopy exam after a positive result on an at-home stool test to screen for colorectal cancer. The test, known as the fecal immunochemical test (FIT), checks for traces of blood in patient-collected stool samples, which can be an...
Nickolas Papadopoulos, PhD, on Multicancer Early Detection: Opportunities and Challenges
Nickolas Papadopoulos, PhD, of the Sidney Kimmel Comprehensive Cancer Center, discusses early detection as the key to reducing cancer mortality and the lack of tests for many malignancies. Liquid biopsies have the potential to screen for various tumor types, albeit with varying levels of...
From a Small Village in China to Cutting-Edge Clinical Cancer Research for Cynthia X. Ma, MD, PhD
Cynthia X. Ma, MD, PhD, was born in a small village in Hebei, a province in the Central China region. “I grew up in a poor village with less than 1,000 people. We had no medical services in our village, so we had to travel to the city to see a doctor, which was quite some distance away. In the...
ASCO Honors 2022 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2022 ASCO Annual Meeting in Chicago. Hear from select award...
Penn Medicine Appoints Robert Vonderheide, MD, DPhil, to Second 5-Year Term as Director of Abramson Cancer Center
Robert H. Vonderheide, MD, DPhil, has been appointed to a second 5-year term as Director of the Abramson Cancer Center (ACC) at the University of Pennsylvania, following a highly successful tenure that saw 17 U.S. Food and Drug Administration approvals in oncology for therapies based on studies...
David Braun, MD, PhD, Joins Prostate and Urologic Cancers Program at Yale Cancer Center
Yale Cancer Center and Smilow Cancer Hospital welcome David Braun, MD, PhD, Assistant Professor of Medicine (Medical Oncology) and a member of the Center for Molecular and Cellular Oncology (CMCO). Dr. Braun cares for patients with kidney cancer. Dr. Braun received his PhD in Computational Biology ...
Sam Mbulaiteye, MBChB, MPhil, MMed, Named 2022 Scientist of the Year by Lymphoma Foundation of America
Sam Mbulaiteye, MBChB, MPhil, MMed, senior investigator in the Infections and Immunoepidemiology Branch, in the Division of Cancer Epidemiology & Genetics of the National Cancer Institute, was recently recognized by the Lymphoma Foundation of America with its 2022 Scientist of the Year Award....
J. Paul Taylor, MD, PhD, Named Scientific Director and Executive Vice President of St. Jude
J. Paul Taylor, MD, PhD, has been named Scientific Director and Executive Vice President of St. Jude Children’s Research Hospital. Dr. Taylor steps into the role during a pivotal time of growth for the hospital. Under its $11.5 billion, 6-year strategic plan, the institution’s scientific...
AACR Honors Lee Ellis, MD, for Contributions to Education and Training in Cancer Research
The American Association for Cancer Research (AACR) has named Lee Ellis, MD, Professor of Colon and Rectal Surgery at The University of Texas MD Anderson Cancer Center, Houston, as the 2022 recipient of the AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in...
POLARIX: Addition of Polatuzumab Vedotin-piiq to Standard of Care Significantly Reduces Progression of Diffuse Large B-Cell Lymphoma
As a first-line treatment of inter-mediate- or high-risk diffuse large B-cell lymphoma, the addition of the antibody-drug conjugate polatuzumab vedotin-piiq to standard-of-care therapy resulted in a 27% reduction in the relative risk of disease progression, relapse, or death, with a similar safety...
Zanubrutinib Superior to Ibrutinib for CLL/SLL in Phase III ALPINE Trial
Zanubrutinib, a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, significantly improved response rates and delayed disease progression as compared with the standard of care, ibrutinib, in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma...
ELEVATE-RR Trial: Acalabrutinib as Effective as Ibrutinib, With Fewer Cardiac Effects, in Resistant CLL
Acalabrutinib was equally efficacious with less toxicity when compared directly with ibrutinib in patients with previously treated relapsed or refractory chronic lymphocytic leukemia (CLL), according to the results of an open-label, randomized, noninferiority phase III trial presented at the 2021...
Charles L. Sawyers, MD, on Transforming Patient Outcomes: The Future of Cancer Research
Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center, discusses the battle against treatment resistance and how to overcome it, as well as the power of observational clinical data in precision oncology, derived largely from his experience with Project GENIE, and the role of genetic...
PSMA-Targeted Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer
In this video, Drs. Celestia (Tia) Higano, Julie Graff, and Neal Shore discuss the role of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy in the treatment of metastatic castration-resistant prostate cancer. The patient is an 81-year-old man with 13-year history of prostate...
Elderly Patient With Metastatic Hormone-Sensitive Prostate Cancer
This is Part 1 of Updates in Prostate Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. �In this video, Drs. Celestia (Tia) Higano, Julie Graff, and Neal Shore discuss the management of metastatic hormone-sensitive prostate cancer in elderly...
Tony Hunter, PhD, FAACR, Honored With 2022 AACR Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) awarded the 2022 AACR Award for Lifetime Achievement in Cancer Research to Tony Hunter, PhD, FAACR, Fellow of the AACR Academy, at its Annual Meeting in New Orleans. Dr. Hunter is the American Cancer Society Professor and Renato Dulbecco Chair at ...
War in Ukraine: Statistics Do Not Keep Pace With Reality
Editor’s Note: The following is adapted from Dr. Hrynkiv’s presentation at the March 18 ASCO/ECO Briefing: Cancer Care During the War in Ukraine. Find resources for impacted patients and providers at asco.org/ukraine and onco-help.org. Official statistics regarding damage and losses in Ukraine are...
Philip D. Greenberg, MD, FAACR, Voted AACR President-Elect for 2022–2023
The members of the American Association for Cancer Research (AACR) have chosen Philip D. Greenberg, MD, FAACR, as the Association’s President-Elect for 2022–2023. Dr. Greenberg is the Rona Jaffe Foundation Endowed Chair and Professor and Head of the Program in Immunology, Clinical Research...
Norman Sharpless, MD, to Step Down as Director of the NCI
Norman E. Sharpless, MD, has announced that he has decided to step down from his position as Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), a position he has held since 2017. Dr. Sharpless will continue as NCI Director through April 29, 2022, to...
Andrew Chapman, DO, FACP, Appointed Director of the Sidney Kimmel Cancer Center–Jefferson Health, Philadelphia
Andrew Chapman, DO, FACP, has been named Director of the Sidney Kimmel Cancer Center–Jefferson Health, with locations in Philadelphia and nearby areas in Pennsylvania and New Jersey. He has also been named the Center’s Executive Vice President for Oncology Services. He has served as the Center’s...
Nominations Open for King Hussein Award for Cancer Research
The Board of Directors for the King Hussein Award for Cancer Research is currently accepting applications for its 2022 honorees. Established in 2020 in memory of His Majesty the late King Hussein bin Talal of Jordan, the award promotes and celebrates cancer research efforts across the Arab world,...
David A. Barbie, MD, on Mesothelioma: Activating the STING Pathway May Promote Antitumor Immunity
David A. Barbie, MD, of Dana-Farber Cancer Institute, discusses his laboratory’s studies, showing that malignant pleural mesothelioma, an inflamed cancer type with marginal response to immune checkpoint blockade, demonstrated high tumor cell STING expression and response to STING agonists in...
Mantle Cell Lymphoma Previously Treated With BTK Inhibitor May Respond to a Newer BTK Inhibitor
The next-generation inhibitor of Bruton’s tyrosine kinase (BTK) may be effective in mantle cell lymphoma for patients previously treated with an older BTK inhibitor, according to results from the phase I/II BRUIN trial. These findings were reported at the 2021 American Society of Hematology (ASH)...
Accounting for Genetic Factors That Cause Normal Variations in PSA Levels May Improve the Accuracy of Prostate Cancer Detection
The accuracy of prostate-specific antigen (PSA) screening for prostate cancer could be improved by accounting for genetic factors that cause changes in PSA levels not associated with cancer, according to data presented by Kachuri et al during the American Association for Cancer Research (AACR)...
Study Examines Disparities in Relapse Among Pediatric Patients With ALL
According to a large multiethnic study presented by Sok et al at the American Association for Cancer Research (AACR) Annual Meeting 2022, Latinx children with acute lymphoblastic leukemia (ALL) and measurable residual disease (MRD)-negative status were more likely to relapse compared with...
Supporting and Mobilizing Resources: ASCO Joins Worldwide Efforts to Support Ukrainian Cancer Care
“Refugees and displaced people may see their cancer treatment interrupted, or they may develop a new cancer while they are in host countries. They often present with advanced disease and suffer more complications. These patients have poor outcomes because of poor hygiene and living conditions, as...
Leader in the Field of Integrative Oncology, Barrie Cassileth, PhD, Dies at 83
In 1999, Memorial Sloan Kettering Cancer Center (MSK) President Paul Marks, MD, recruited Barrie Cassileth, PhD, to establish an Integrative Medicine Service that “provided evidence-based complementary therapies that improve patients’ quality of life by alleviating physical and emotional symptoms...
Childhood Leukemia Pioneer, Donald P. Pinkel, MD, Dies at 95
When St. Jude Children’s Research Hospital was opened in 1962, childhood blood cancer, especially acute lymphoblastic leukemia (ALL), had an exceptionally grim prognosis. However, years of unflagging clinical research led by Donald P. Pinkel, MD, the pediatrician who developed an aggressive...
A Lifetime of Pioneering Biologic Research Leads to a New History of Evolution
Although The Social Conquest of Earth was published a decade ago, it is worth revisiting, because, as oncology luminary Harold Varmus, MD, stressed: “It is a tour de force that we ignore at our planet’s peril.” Its author, Edward O. Wilson, PhD, known as “the father of sociobiology,” died at the...
Conundrums of SARS–CoV-2 Infection in Cancer Care
The ASCO Post is pleased to present the Hematology Expert Review, an occasional feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib, Kröger, and Mikulska focus on the challenges of providing cancer care amid the COVID-19 pandemic. Here they present two...
Jeffrey Peppercorn, MD, MPH, Named Editor-in-Chief of JCO Oncology Practice
Jeffrey Peppercorn, MD, MPH, has been appointed as the next Editor-in-Chief of the ASCO journal JCO Oncology Practice (JCO OP). The journal publishes impactful information and insights to keep oncology practice current on changes and challenges inherent in delivering equitable, high-quality...
Seven New Research Grants Awarded by The Prevent Cancer Foundation
The Prevent Cancer Foundation recently announced funding for seven scientists who are researching cancer prevention and early detection. Each scientist has been awarded $100,000 for 2 years. The following individuals are the 2022 research grantees: Sarah Bernhardt, PhD, Postdoctoral Fellow Oregon...
Brazilian Oncologist Antônio Drauzio Varella, MD, Rises From the Streets of São Paulo to International Fame
In this edition of Living a Full Life, Guest Editor Jame Abraham, MD, spoke with Antônio Drauzio Varella, MD, a Brazilian oncologist, educator, scientist, and medical science popularizer in the press and television, as well as a best-selling author. Antônio Drauzio Varella, MD, was born in 1943 in ...
Trials of PARP Inhibitors in Urothelial Cancer: More Questions Than Answers?
Two studies presented at the 2022 ASCO Genitourinary Cancers Symposium explored the role of poly (ADP-ribose) polymerase (PARP) inhibitors in urothelial cancer: ATLANTIS and BAYOU.1,2 Results suggest that PARP inhibitors may be useful in certain genetic subgroups and perhaps in combination with...
Advances in Managing Cardiac Side Effects Associated With Breast Cancer Treatment
Guideline-directed medical therapy for the prevention and treatment of cardiotoxicity is improving quality of life and oncologic outcomes associated with breast cancer treatment, according to Jean-Bernard Durand, MD, FACP, FCCP, FACC, FHFSA, Professor of Medicine at The University of Texas MD...
Norman Sharpless, MD, to Step Down as Director of the NCI
Norman E. Sharpless, MD, has announced that he has decided to step down from his position as Director of the National Cancer Institute (NCI), part of the National Institutes of Health, a position he has held since 2017. Dr. Sharpless will continue as NCI Director through April 29, 2022, to allow...
Therapy Options for Primary Refractory FLT3-ITD–Positive AML
In this video, Drs. Richard Stone, Courtney DiNardo, and Eunice Wang treatment options for primary refractory FLT3-ITD–positive acute myeloid leukemia (AML). The case is a 60-year-old man with a history of hypertension and hyperlipidemia who presents with fatigue. He is diagnosed with...
How ASCO, ECO, and WHO Are Marshalling Resources to Provide Care for Ukrainian Civilians and Refugees With Cancer
Since Russia invaded Ukraine on February 24, the number of attacks on health-care facilities continues to mount. According to the World Health Organization (WHO), as of March 16, there have been 43 attacks on health facilities, including 34 attacks that have directly impacted health facilities and...
American Cancer Society Names Arif Kamal, MD, First Chief Patient Officer
The American Cancer Society (ACS) has named Arif Kamal, MD, MBA, MHS, FACP, FAAHPM, FASCO, as its first Chief Patient Officer to lead its patient support vision and strategic plans to improve the lives of patients with cancer and their families. Based in Chapel Hill, North Carolina, Dr. Kamal will ...
New Role for Raymond N. DuBois, MD, PhD, FAACR, at The Mark Foundation for Cancer Research
Raymond N. DuBois, MD, PhD, FAACR, was recently appointed Executive Chairman of the Board of The Mark Foundation for Cancer Research. Dr. DuBois is Director of the Medical University of South Carolina (MUSC) Hollings Cancer Center and Distinguished University Professor at MUSC. As The Mark...
Robert Otto Valdez, PhD, MHSA, Named Director of the AHRQ
Robert Otto Valdez, PhD, MHSA, was appointed Director of the Agency for Healthcare Research and Quality (AHRQ) in February 2022. He was previously the Robert Wood Johnson Foundation (RWJF) Professor Emeritus of Family & Community Medicine and Economics at the University of New Mexico (UNM). In...
ACCC Appoints David R. Penberthy, MD, MBA, as New President
David R. Penberthy, MD, MBA, was recently named President of the Association of Community Cancer Centers (ACCC) at the organization’s 48th Annual Meeting and Cancer Center Business Summit. Oncology professionals from around the nation gathered at the conference to discuss the convergence of...
Arul Chinnaiyan, MD, PhD, Awarded Sjöberg Prize for Cancer Research
The Royal Swedish Academy of Sciences, which also awards Nobel Prizes, has announced the winner of the 2022 Sjöberg Prize. Arul Chinnaiyan, MD, PhD, S.P. Hicks Professor of Pathology and Urology at Michigan Medicine, is being honored for the discovery of recurrent gene fusions in prostate cancer....
ACCC Welcomes Matt Devino, MPH, as Director, Cancer Care Delivery and Health Policy
The Association of Community Cancer Centers (ACCC) announced that Matt Devino, MPH, has joined the organization as Director, Cancer Care Delivery and Health Policy. Mr. Devino will lead the organization’s initiatives to improve cancer care delivery and promote health equity across rural, urban,...
The University of Texas MD Anderson Cancer Center Launches James P. Allison Institute
Today, The University of Texas MD Anderson Cancer Center launched the James P. Allison Institute, a visionary research and innovation hub within MD Anderson designed to foster groundbreaking science, to develop new treatments, and to bring the benefits of immunotherapy to all patients. The Allison...
Researchers Identify Trends in Treatment for Retroperitoneal Soft-Tissue Sarcoma
Researchers have published an analysis of strategies for treating retroperitoneal soft-tissue sarcoma, which has historically been understudied due to its rarity. The researchers say the trends they identified—particularly the convergence of certain treatments across centers—will help guide the way ...
VISION Trial: Novel PSMA-Targeted Radiotherapy Improves Outcomes in Metastatic Prostate Cancer
Lutetium-177–PSMA-617 (LuPSMA)—an investigational radiolabeled small molecule—significantly improved radiographic progression-free survival and overall survival when added to the standard of care compared with the standard of care alone for men with metastatic castration-resistant prostate cancer...
